Please assess the completion status of the following clinical trial:

Trial Title: OsteoCool Tumor Ablation Post-Market Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Candidate for OsteoCool RF ablation per the labeled indication applicable in their respective country/region~2. A. Metastatic lesions targeted for treatment must be located in the thoracic and/or lumbar vertebral body(ies), periacetabulum, iliac crest, and/or sacrum OR benign bone tumors - no restrictions on location of lesion~3. Report worst pain score ≥4/10 at the target treatment site within the past 24 hours~4. Localized pain resulting from no more than two sites total of metastatic disease~5. Have Karnofsky score ≥40 at enrollment (not applicable for subjects with benign bone tumors)~6. Willing and able to provide a signed and dated informed consent, comply with the study plan, follow up visits and phone calls~7. At least 18 years old at the time of informed consent~Exclusion Criteria:~1. A. Implanted with heart pacemaker or other implanted electronic device (Europe and Canada only)~2. Use of OsteoCool in vertebral body levels C1-C7~3. Multiple myeloma, solitary plasmacytoma, or primary malignant lesions in the index vertebra or bone~4. Active or incompletely treated local infection at the planned treatment site(s) and/or systemic infection~5. Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise~6. Planned treatment site(s) associated with spinal cord compression or canal compromise requiring decompression~7. Fractures due to prostatic cancer or other osteoblastic metastases to the spine. Metastatic lesions originating in the prostate that are osteolytic or mixed origin are eligible for the study~8. Pregnant, breastfeeding, or plan to become pregnant during the study duration~9. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results\*~10. Any condition that would interfere with the subject's ability to comply with study instructions or might confound the study interpretation~    * Subjects in concurrent studies can only be enrolled with permission from Medtronic. Please contact Medtronic's study manager to determine if the subject can be enrolled in both studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OsteoCool™ RF Ablation (Type: OTHER): Subjects will undergo a single OsteoCool™ RF Ablation procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).